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Aims: To assess the impact of sampling bias due to reported as well as unreported exclusion of the 
target population in a multi-center randomized controlled trial (RCT) of ST-elevation myocardial 
infarction (STEMI). 
Methods and Results: We compared clinical characteristics and mortality between participants in 
the DANAMI-3 trial to contemporary non-participants with STEMI using unselected registries. A 
total of 179 DANAMI-3 participants (8%) and 617 contemporary non-participants (22%) had died 
(Log-Rank: P<0.001) after a median follow-up of 1333 days (range: 1-2021 days).  In an  unadjusted 
cox regression model all groups of non-participants had a higher hazard ratio to predict mortality 
compared to participants:  eligible excluded (n=144) (hazard ratio: 3.41 (95%CI: (2.69-4.32)), 
ineligible excluded (n=472) (hazard ratio: 3.42 (95%CI: (2.44-4.80),  eligible non-screened (n=154) 
(hazard ratio: 3.37 (95%CI: (2.36-4.82)), ineligible non-screened (n=154) (hazard ratio: 6.48 (95%CI: 
(4.77-8.80). 
Conclusion:  Sampling bias had occurred due to both reported and unreported exclusion of eligible 
patients and the difference in mortality between participants and non-participants could not be 
explained only by the trial exclusion criteria. Thus, screening logs may not be suited to address the 
risks of sampling bias. 
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In randomized controlled trials determinants of external validity are rarely reported [1]. Patients with 
high risk characteristics are often excluded due to predefined exclusion criteria which can lead to 
major differences between participants and non-participants [2;3]. The requirement for informed 
consent and  issues related to timing and the complexity of clinical trial protocols could also result in 
missed inclusion of the per-protocol desires study population (target population).  Sampling bias can 
be introduced by resistance to participate by eligible patients, practical challenges and violation of 
the pre-defined eligibility criteria resulting in differences in characteristics between participants and 
non-participants related to risk of i.e. cardiovascular outcomes [4]. In recently published RCTs with 
patients with STEMI reasons for exclusion of patients are usually reported only from the screening 
logs to describe the selection of study participants and the risk of sampling bias. However, screening 
rates as well as characteristics and prognosis for the non-screened target population are rarely 
accounted for in the trial screening log.  
Previous studies have investigated external validity in RCTs of acute myocardial infarction [5-7]. 
However, most studies have compared trial participants to non-participants from selected registries 
or to the excluded patients from the trial screening log only. The issue of sampling bias due to 
unreported screening and exclusion of eligible patients with STEMI has, to our knowledge, not been 
addressed. In this study we assessed the external validity in a national multi-centre RCT of STEMI 
with all-comers design conducted in Denmark [8-10]. We compared participants in the “The Third 
Danish Study of Optimal Acute Treatment of Patients with ST-segment elevation Myocardial 
Infarction” (DANAMI-3) trial to contemporary non-participants. We evaluated the impact of trial 
exclusion criteria as well as the impact of sampling bias from both reported exclusion in the trial 
screening log and unreported exclusion of eligible patients with STEMI using unselected national 

















2.1 Patients and databases 
Since 2002 reperfusion with primary percutaneous coronary intervention (pPCI) has been standard 
of care for patients with STEMI in Denmark and each pPCI procedure has been recorded in the two 
Danish Heart registries (the Eastern and Western Danish Heart Registry). The registries were 
designed for safety, administrative and research purposes and contain baseline and procedural 
information about every single consecutive pPCI for patients with STEMI. The DANAMI-3- trial 
was an investigator-initiated all-comers national multicenter, randomized controlled trial with 
endpoint design and with participation from all four pPCI-centres in Denmark [9]. The inclusion 
started March 21st 2011 to February 2nd 2014 in the top including study site.  The study population in 
the present study constitutes all patients admitted with STEMI in Denmark during the DANAMI-3 
inclusion period in the top participating study site. All patients in this study were identified through 
the heart registries and the DANAMI-3 screening log. In the top including study site the aim was to 
formally screen all consecutive patients with STEMI for study eligibility during the inclusion period. 
The decision to enrol a patient was made by the pPCI-operator before the pPCI procedure and 
variables related to treatment specifics were reported and stored immediately after completion of the 
pPCI regardless of study participation by an on-site study nurse. The inclusion criteria for DANAMI-
3 were >18 years, acute onset of chest pain with ≤12 hours and ST-segment elevation in the ECG. 
The exclusion criteria were suspected pregnancy, intolerance to aspirin or P2Y12-receptor antagonists, 
inability to provide signed consent, cardiogenic shock, unconsciousness, indication for CABG, stent 
thrombosis or coagulopathy. Reasons for exclusion from DANAMI-3 were recorded in the trial 
screening log. Information about existing comorbidity (ICD-10-classifications) was obtained from 
the Danish National Patient Registry using a unique 10-digit civil person registration number assigned 
















information on vital status and causes of death were obtained for all patients from the Danish 
Centralized Civil Registry and the Cause of Death Registry also using the civil person registration 
number. Patients without Danish civil person registration number (e.g. tourists) were excluded from 
analysis due to missing data on vital status and comorbidities in the national registries.  
For the main analysis the comparative groups were patients >18 years treated with pPCI and 
presenting with STEMI <12 hours after symptom onset in the DANAMI-3 inclusion period who 1) 
participated in DANAMI-3 (participants), 2) did not participate in DANAMI-3 and who were 
recorded in the trial screening log (excluded) and 3) did not participate and were not recorded in the 
trial screening log (non-screened). To assess the impact of the exclusion criteria and the issue of 
sampling bias we also compared participants to 1) eligible non-participants (non-participants without 
exclusion criteria) 2) ineligible non-participants (non-participants with exclusion criteria). 
Participants were also compared to 1) eligible excluded (excluded patients without exclusion criteria), 
2) ineligible excluded (excluded with exclusion criteria), 3) eligible non-screened (non-screened 
without exclusion criteria) and finally 4) ineligible non-screened (non-screened with exclusion 
criteria). 
Characteristics and endpoints 
Differences in baseline clinical characteristics which are known to be associated with higher risk and 
procedure-related variables which could be associated with sampling bias were assessed between the 
comparative groups from the top including study site. We compared differences in demographics, 
cardiovascular risk factors, and known predictors of mortality including clinical presentation at 
admission [11] and comorbidity present at the time of the pPCI [12;13]. Cancer included all ICD10 
cancer classifications with or without metastasis. All cardiac rhythms except sinus rhythm, first 
degree atrium-ventricular block, bundle branch block, ventricular fibrillation and ventricular 
















cardiac arrhythmias VF/VT were assessed separately and included patients with at least one 
documented episode of VF/VT prior to admission where unconsciousness was not recorded in the 
patient records. Unconsciousness included unconscious patients with return of spontaneous 
circulation following documented VF/VT. All patients with VF/VT were assessed manually in local 
electronic patient files to assess if they were unconscious at the time of admission. Heart failure was 
classified as comorbidity if the condition was known prior to the PCI-procedure.  Information about 
all base-line characteristics was available for all patients in the heart registries. All the non-screened 
patients from the top including study site were assessed manually for exclusion criteria in the local 
electronic patient records and the STEMI diagnosis was confirmed. The patients were followed until 
death, emigration or the termination date of this study (September 31st 2016).  Mortality was reported 
during the entire follow-up period, at 30-days and from 30 days to the end of follow-up. The National 
Board of Health (case file no 3-3013-1227/1/Reference SABN) and the Danish Data Protection 
Agency (case file no. 30-1286, 03727) gave its permission to cross-check data from electronic patient 
files at the pPCI centers and from public registries.  
2.3 Data-analysis and statistical considerations 
Categorical variables were presented as numbers and percentages and compared using the Chi2 or 
Fisher´s exact tests. Continuous variables were evaluated for normal distribution by visual assessment 
of histograms and compared by means ±SD using one-way independent ANOVA or by median (25-
75 interquartile range) Kruskal-Wallis test as appropriate. Post-hoc adjustment for multiple 
comparisons was performed in one-way Anova and Kruskal-Wallis test using Tukey-Kramer 
correction. . .Comparison of event free survival between participants and non-participants was 
performed visually by Kaplan-Meier curves and statistically by the Log-rank test. All-cause mortality 
was used as an endpoint to explore the difference in total risk over time between all groups and is a 
















hazard models were used to calculate the unadjusted hazard ratios along with 95% confidence 
intervals between participants and four groups of non-participants. The model was assessed for 
proportionality of hazards and interactions. Missing data was handled with  x20 multiple imputations  
by chained equations [14]  as the data was not missing completely at random. Variables with missing 
data less than 15% were imputed and variables with more than 15% of cases were excluded from 
analysis. SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for 
statistical analysis.  
3. Results:  
During the DANAMI-3-study period a total of 5061 patients >18 years with STEMI and symptom 
duration <12 hours were admitted and treated with pPCI in Denmark in the four participating study 
sites (figure 1).  A total of 2206 (43%) of these patients were included in DANAMI-3 and the 
inclusion rates varied from 5%-63% between the four participating study sites. At the top including 
study site (centre 1) a total of 1601 patients (64%) were included in the trial (73% of the overall study 
population) and 605 (24%) patients were excluded for reasons listed in the trial screening log (figure 
1). A total of 308 patients (12%) were not screened for eligibility/not recorded in the trial screening 
log at the top including study site. Following retrospective manual assessment, DANAMI-3 eligibility 
of the non-screened patients was listed and 154 (6%) patients in this group did not have exclusion 
criteria (figure 1).  After randomization 27 patients dropped out before discharge from hospital due 
to withdrawal of consent and they were categorized as participants in this analysis. Of the excluded 
patients 144 (5%) did not, after thorough studying of hospital charts, have any per-protocol defined 
exclusion criteria but were excluded due to participation in other studies, short life expectancy, 
logistic reasons (two or more STEMI requiring acute treatment at the same time), expected poor 
patient compliance or comorbidity. Unconsciousness/cardiogenic shock (30%), inability to sign 
















frequent reason for per-protocol exclusion. The ethics committee did not permit collection of reasons 
for refusal by patients.  
3.1 Baseline characteristics 
In table 1 (e-component 1) all clinical characteristics at were compared between participants, 
excluded and non-screened patients from the top including study site. DANAMI-3-participants were 
younger, had fewer risk factors (except for smoking status) and less frequently comorbidities. The 
clinical presentation by participants at admission was also significantly different than the two other 
groups and the participants had shorter duration from symptom onset to first wire and were treated 
more often during office hours. The excluded had similar characteristics compared to the non-
screened patients except for cardiac arrhythmias, systolic blood pressure, cardiogenic shock and stent 
thrombosis (P for all <0.001) end were less frequently treated during off-hours (P<0.001) and has less 
language and communicational issues (P<0.001). A total of 131 of the non-screened patients did not 
have an exclusion criterion and were not screened for unknown reasons (figure 1). For these patients 
54% were available for formal screening during weekdays in day time (8 a.m - 4 p.m) compared to 
32 % of the participants (data not shown). 
  
3.3 Mortality 
All-cause mortality was used as an endpoint to explore the difference in the combined clinical 
longitudinal risk between the groups. For all patients with STEMI treated with pPCI in Denmark 
during the DANAMI-3 inclusion period a total of 478 patients (9.8%) died after 1 year follow-up and 
796 patients (16%) after a median follow-up of 1333 days (range: 1-2021 days). At the top including 
study site the recorded screening rate was 88% and mortality was significantly lower among the 
















p<0.001) after a median follow up of 1377 days (range: 1-2021) (figure 2). The difference in mortality 
was also significantly lower from 1-30 days among participants (2%) compared to excluded (13%) 
and non-screened (22%) (Log-Rank:  p<0.001) and also from 30 days to the end of follow-up for 
participants (7%) compared to excluded (16%) and non-screened (16%) (Log-Rank: p<0.001).  After 
5 days there was no significant difference in mortality between excluded (18%) and non-screened 
(19%) (Log-Rank: p=0.65).  Participant had lower mortality (9%) compared to eligible non-
participants (30%) and  ineligible non-participants (28%) (Log-Rank: p<0.001) (figure 3). There was 
no difference in mortality between eligible non-participants and ineligible non-participants. 
Participants had a lower hazard ratio for mortality (9%) compared to both eligible excluded (26%) 
and ineligible excluded (27%) patients as well as compared to eligible non-screened (27%) and 
ineligible non-screened patients (42%) (Log-Rank for all P <0.001) (table 2).  
  
4 Discussion  
In this study we were able to compare participants in a RCT of STEMI with contemporary excluded 
and non-screened patients from the top inclusion study site through unselected registries. The two 
main findings were: 1) Non-screened had similar characteristics and all-cause mortality compared to 
the excluded patients and thus unreported screening and exclusion of the target population had 
occurred. 2) Participants had a lower mortality rate compared to eligible excluded and eligible non-
screened and may therefore not be representative to the entire target population without exclusion 
criteria.  
RCTs are the gold standard to test efficacy and safety in evidence based medicine, and the results 
from a well-executed RCT with strong internal validity and without sampling bias can be extrapolated 
















RCTs have a better prognosis than patients not included in RCTs of acute coronary syndromes [5;6] 
including RCTs with all-comers design [2;3]. It is also acknowledged that patients with exclusion 
criteria represent patients with higher risk and have a worse prognosis than patients without exclusion 
criteria [5]. In addition, sampling bias can be a source of poor external validity because eligible 
patients who are screened for study inclusion, but not randomized, have a worse prognosis compared 
to participants [15].  
The results from this study consisted with previous results that sampling bias can occur due to 
exclusion of eligible patients recorded in the screening logs. We also suggested that the full extent of 
sampling bias cannot be assessed using screening logs because not all screening and exclusion of 
eligible patients is recorded in screening logs. As a result of investigator incentives a great proportion 
of patients in the non-screened group were probably bypassed from the DANAMI-3 screening log 
and these patients constituted a source of sampling bias. Comparison of mortality between 
participants and both eligible and ineligible non-participants supports the findings that exclusion of 
eligible patients and sampling bias had occurred and that the differences between participants and 
non-participants could not be only due to exclusion criteria (figure 3).  If screened patients are not 
recorded in the trial screening log it is difficult to assess the representativity of the trial participants 
in the absence of unselected registry data. The Danish heart registries, The National Cardiovascular 
Data Registry [16] and the SCAAR registry [17] are examples of databases, which contain unselected 
routinely collected clinical data according to European data standards for clinical care in cardiology 
[18]. Such registries represent important infrastructures for reporting important determinants of 
external validity in RCTs.  
We showed that participants had a different baseline profile compared to patients who were excluded 
from the trial as well as patients who were not screened in the top including study site.  Both short-
















average of predicted risk and long-term mortality predictors in the excluded and non-screened.. In 
DANAMI-3 the effect of the intervention did not show any beneficial effect on mortality. Thus, the 
difference between participants and non-participants could not be due to treatment effects. We also 
recognize performance bias to be a potential factor for the difference between the groups. 
Unfortunately, we were not able to explore this parameter 
 Reasons for unreported exclusion of eligible patients are difficult to address and are most likely 
multifactorial. In this study 50% (154 patients) of the non-screened had an exclusion criterion. 
However, 44% (131 patients) of the non-screened did not have an exclusion criterion and were not 
recorded in the screening log for unknown reasons. We were not able to show any statistically 
significant correlation between non-screening for unknown reasons and any of the examined 
parameters. Importantly, non-screening would not have been expected to result in sampling bias if 
non-screening was due to random circumstancesBased on the results from this study the results from 
DANAMI-3 in the top including study site could not be extrapolated to patients with exclusion criteria 
(26%) because they showed different prognosis compared to participants. In addition, the results 
could not be extrapolated to eligible non-participants (12%) and extrapolation of results may be 
limited to patients with similar characteristics as participants. The present inclusion rate of 43% in 
the DANAMI-3 from the Danish population with STEMI is only comparable to one other 
contemporary RCT of STEMI patients treated with pPCI [19] because most RCTs do not report 
inclusion rates at all. The recorded screening rate of 88% in the top including study site was more 
difficult to compare to other studies because formal screening of the target population could 
potentially be defined in different ways. The protocol in DANAMI-3 stated that only the top including 
study site was committed to record all consecutive patients from the target population in the trial 
















eligibility and clinical course for the non-screened patients (or a random sample of this group) is 
important to evaluate the relative size of the sample and extend of sampling bias. 
The ability of RCTs to represent a true population with STEMI patients is potentially hampered by 
several issues as shown in this study.  First, protocolled exclusion criteria are applied due to ethical- 
or safety considerations from the investigators or ethics committees. Secondly, patients with STEMI 
represent a group of critically ill patients and immediate informed consent is difficult to obtain from 
a large proportion of the most critically ill patients. Third, screening in the acute setting of STEMI 
must be done by research personal available, which can be sparse during off hours and acute 
lifesaving treatment must not be delayed. Failure to obtain informed consent prior to study inclusion 
has been a concern for external validity in previous RCTs of acute myocardial infarction [2] and at 
least one contemporary study had ethical approval to obtain what was labelled “delayed informed 
consent” after study inclusion which is a way to improve inclusion rates [7]. In the DANAMI-3 study 
149 (24%) of the excluded and 105 (32%) of the non-screened were unconscious after out of hospital 
cardiac arrest or presented with cardiogenic shock and these characteristics are also known predictors 
of mortality. The failure to include the most critically ill patients may compromise the ability of a 
RCT with STEMI patients to assess short term effectiveness of a new treatment.  Proxy consent of 
trial inclusion for the most critically ill patients could potentially help to overcome this issue. Failure 
to include the chronically ill patients could also compromise external validity and long term 
effectiveness assessment. The long term clinical course for the participants was consistent with the 
lower prevalence of risk factors and comorbidities, which are known predictors of mortality.  
 
















This study is largely based on data based on data from a single centre. In addition, we were not able 
to assess the impact of all exclusion criteria because information about refusal and intolerance to 
aspirin or P2Y12-receptor antagonists were not available for all patients.   
5. Conclusion 
In a national multicenter all-comers randomized controlled trial of STEMI patients treated with pPCI, 
the participants had a lower mortality rate than contemporary patients who did not participate. 
Sampling bias occurred due to both reported and unreported exclusion of eligible patients and the 
difference in mortality between participants and non-participants could not be explained only by the 
trial exclusion criteria. Thus, sampling bias may represent a caveat when performing randomized all-
comers STEMI studies and screening logs are potentially not suited to address this bias in RCTs.  
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Table and figure legends 
 
Table 2 
Hazard ratios according to screening status and eligibility 
 
Unadjusted cox-regression analysis of the relationship between all-cause mortality and DANAMI-3 screening status in the top 






































Mortality according to DANAMI-3 eligibility 
 
Kaplan-Meier curves for event-free survival for DANAMI3 participants, eligible non-participants and ineligible non-






















  n Hazard Ratio (95% CI) P 
Participants 1564 1     
Excluded- eligible 144 3.41 (2.69-4.32) <0.001 
Excluded- ineligible 488 3.42 (2.44-4.80) <0.001 
Non-screened- eligible 154 3.37 (2.36-4.82) <0.001 



















 Participants in the DANAMI-3 trial were not representative to the background population 
with STEMI 
 Participants in the DANAMI-3 trial were not representative to the per protocol target 
population 
 Sampling bias and unreported screening had occurred 
  
 Screening logs may not be suitable for addressing issues of external validity 
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